Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2014

View Archived Issues

Sideris initiates phase I study of SP-420 in beta-thalassemia

Felicitex Therapeutics and Selvita target cancer quiescence through new collaboration

BIND Therapeutics collaborates with Merck & Co to develop nanomedicines for oncology

REP1 gene therapy granted FDA orphan drug designation for choroideremia

Idera and PPMD collaborate to develop TLR antagonist for Duchenne muscular dystrophy

QUE Oncology reports data from phase I study of Q-122

PRX-106, a plant cell-expressed recombinant fusion protein as treatment for fatty liver disease

Safety and favorable pharmacokinetic profile of GR-MD-02 supports plans for phase II trials

Karyopharm begins phase II trial of selinexor in patients with Richter's transformation

ZGN-203, a novel MetAP 2 inhibitor for weight loss and hyperphagia correction

Emergent seeks FDA approval of BioThrax for post-exposure prophylaxis indication

Sage's phase I/II study of SAGE-547 for super-refractory status epilepticus meets endpoints

Pierre Fabre patents report compounds with potential use in cancer

BeiGene researchers divulge BTK inhibitors

Crucell reports antibodies targeting RSV G protein

Astex Pharmaceuticals discloses FGFR inhibitors for cancer

AVEO Pharma designs anti-Notch 1 MAbs

TetraLogic Pharmaceuticals reports data from preclinical studies of birinapant

Researchers in Slovakia develop curcumin palladium complexes and analogues

Hanmi files Korean IND for phase I trial of RAF inhibitor

Dulaglutide now available in the U.S.

RedHill Biopharma's RHB-105 gains FDA QIDP designation

Promising interim analysis from phase IIb study of dupilumab for moderate to severe asthma

Oncothyreon and Celldex start phase I trial of MUC1 vaccine and anti-CD27 antibody combination

ELQ-337, a prodrug with enhanced delivery and efficacy in malaria models

ASK-1 inhibitor GS-444217 blocks hepatic fibrosis and steatosis in murine models

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...